We observed extra-telomeric binding of the telomere repeat binding factor TRF2 within the promoter of the cyclin-dependent kinase CDKNIA (p21/CIP1/WAF1). This result in TRF2 induced transcription repression of p21. Interestingly, p21 repression was through engagement of the REST-coREST-LSD1-repressor complex and altered histone marks at the p21 promoter in a TRF2-dependent fashion. Furthermore, mutational analysis shows p21 repression requires interaction of TRF2 with a p21 promoter G-quadruplex. Physiologically, TRF2-mediated p21 repression attenuated drug-induced activation of cellular DNA damage response by evading G2/M arrest in cancer cells. Together these reveal for the first time role of TRF2 in REST- repressor complex mediated transcription repression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599563 | PMC |
| http://dx.doi.org/10.1038/s41598-017-11177-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Royal Jelly Maintains Epidermal Stem Cell Properties by Repressing Senescence.
Biol Pharm Bull
December 2024
Pharmaceutical Research and Technology Institute, Kindai University.
Royal jelly (RJ), a natural product secreted by honeybees, is widely used in topical skincare products to help maintain cutaneous homeostasis. Despite its popularity, the mechanism through which RJ exerts its effects on the skin has not been fully elucidated. This study aimed to explore the impact of RJ on the proliferative ability and senescence of human primary epidermal keratinocytes (HPEKs).
View Article and Find Full Text PDFMYT1L deficiency impairs excitatory neuron trajectory during cortical development.
Nat Commun
November 2024
Department of Genetics, Washington University School of Medicine, Saint Louis, MO, USA.
Mutations reducing the function of MYT1L, a neuron-specific transcription factor, are associated with a syndromic neurodevelopmental disorder. MYT1L is used as a pro-neural factor in fibroblast-to-neuron transdifferentiation and is hypothesized to influence neuronal specification and maturation, but it is not clear which neuron types are most impacted by MYT1L loss. In this study, we profile 412,132 nuclei from the forebrains of wild-type and MYT1L-deficient mice at three developmental stages: E14 at the peak of neurogenesis, P1 when cortical neurons have been born, and P21 when neurons are maturing, to examine the role of MYT1L levels on neuronal development.
View Article and Find Full Text PDFPRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis.
Cancers (Basel)
November 2024
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Protein arginine methyltransferase 5 (PRMT5) is a critical oncogenic factor in various cancers, and its inhibition has shown promise in suppressing tumor growth. However, the role of PRMT5 in squamous cell carcinoma (SCC) remains largely unexplored. In this study, we analyzed SCC patient data from The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map (DepMap) to investigate the relationship between PRMT5 and SCC proliferation.
View Article and Find Full Text PDFKGF secreted from HSCs activates PAK4/BMI1, promotes HCC stemness through PI3K/AKT pathway.
IUBMB Life
January 2025
Department of Hepatopancreatobiliary Surgery, Jiangyin People's Hospital Affiliated to Nantong University, China.
In our present study, we investigated the interaction between HSCs and HCC, also explored the molecular mechanism. Clinical samples were collected from HCC and adjacent tissue with different degree of liver fibrosis. HCC cells were co-cultured with LX-2 cell by Transwell system or cultured with conditioned medium (CM), which was collected from LX-2.
View Article and Find Full Text PDFReactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRAS inhibitor resistant tumors.
Redox Biol
December 2024
State Key Laboratory of Natural Medicines, Department of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China. Electronic address:
Article Synopsis
- KRAS inhibitors like AMG510 and MRTX849 show limited clinical success due to the development of resistance in cancer cells, highlighting the need for new treatments.
- Researchers created resistant KRAS mutant cancer cell lines and tested FDA-approved drugs, discovering that ferroptosis inducers like sorafenib and lapatinib effectively inhibited growth in these resistant cells.
- The resistance mechanism involves reactivation of MAPK signaling, leading to reduced expression of key transporters, which increases sensitivity to ferroptosis; ultimately, this study suggests that ferroptosis inducers may provide a promising strategy for treating patients with G12Ci resistant cancers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!